High Per-Capita Spending On Medicines Creates Revenue Earning Opportunities For Drugmakers

BMI View: Despite the threat of austerity measures, the Swiss government's focus on cost-containment within the pharmaceuticals and healthcare sector and the impact of generic competition as a result of the patent cliff, we expect Switzerland to remain attractive to innovative drugmakers. Furthermore, per-capita spending is high, there is a sizeable pensionable population and regulations are transparent - factors BMI believes will continue to bring in substantial income for companies operating in the country.

To read the full article, please choose one of the following options: